These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15920466)

  • 1. In vivo snapshots of the dopaminergic synapse in small animals.
    Nikolaus S; Beu M; Wirrwar A; Antke C; Müller HW
    Mol Psychiatry; 2005 Jun; 10(6):516-8. PubMed ID: 15920466
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine receptors in Parkinson's disease: imaging studies.
    Stoessl AJ; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():65-71. PubMed ID: 12442664
    [No Abstract]   [Full Text] [Related]  

  • 3. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and "intrasynaptic" transmitter.
    Innis RB
    Adv Pharmacol; 1998; 42():215-9. PubMed ID: 9327882
    [No Abstract]   [Full Text] [Related]  

  • 4. Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact.
    Catafau AM
    Nucl Med Commun; 2001 Oct; 22(10):1059-60. PubMed ID: 11567176
    [No Abstract]   [Full Text] [Related]  

  • 5. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands.
    Tatsch K; Asenbaum S; Bartenstein P; Catafau A; Halldin C; Pilowsky LS; Pupi A;
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):BP30-5. PubMed ID: 12436496
    [No Abstract]   [Full Text] [Related]  

  • 6. Geometry and kinetics of dopaminergic transmission in the rat striatum and in mice lacking the dopamine transporter.
    Gonon F; Burie JB; Jaber M; Benoit-Marand M; Dumartin B; Bloch B
    Prog Brain Res; 2000; 125():291-302. PubMed ID: 11098665
    [No Abstract]   [Full Text] [Related]  

  • 7. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuroimaging present and future].
    Fukuyama H
    No To Shinkei; 2005 May; 57(5):387-96. PubMed ID: 15981638
    [No Abstract]   [Full Text] [Related]  

  • 9. New clues to brain dopamine control, cocaine addiction.
    Balter M
    Science; 1996 Feb; 271(5251):909. PubMed ID: 8584927
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites).
    Stoessl AJ; Ruth TJ
    Curr Opin Neurol; 1998 Aug; 11(4):327-33. PubMed ID: 9725078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease.
    Morrish P
    Mov Disord; 2005 Jan; 20(1):117; author reply 117-8. PubMed ID: 15468100
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.
    Dresel SH; Kung MP; Huang XF; Plössl K; Hou C; Meegalla SK; Patselas G; Mu M; Saffer JR; Kung HF
    J Nucl Med; 1999 Apr; 40(4):660-6. PubMed ID: 10210226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6.
    Wüllner U; Reimold M; Abele M; Bürk K; Minnerop M; Dohmen BM; Machulla HJ; Bares R; Klockgether T
    Arch Neurol; 2005 Aug; 62(8):1280-5. PubMed ID: 16087769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?
    Sidhu A; Wersinger C; Vernier P
    FASEB J; 2004 Apr; 18(6):637-47. PubMed ID: 15054086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography.
    Booij J; de Bruin K; Habraken JB; Voorn P
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1221-4. PubMed ID: 12418461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Albin RL; Nichols TE; Frey KA
    JAMA; 2002 Jul; 288(3):311-2; author reply 312-3. PubMed ID: 12117386
    [No Abstract]   [Full Text] [Related]  

  • 17. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease.
    Morrish PK
    JAMA; 2002 Jul; 288(3):312; author reply 312-3. PubMed ID: 12117387
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT.
    van der Wee NJ; Stevens H; Hardeman JA; Mandl RC; Denys DA; van Megen HJ; Kahn RS; Westenberg HM
    Am J Psychiatry; 2004 Dec; 161(12):2201-6. PubMed ID: 15569890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-beta-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry.
    Riikonen RS; Nokelainen P; Valkonen K; Kolehmainen AI; Kumpulainen KI; Könönen M; Vanninen RL; Kuikka JT
    Biol Psychiatry; 2005 Jun; 57(12):1565-72. PubMed ID: 15953494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.
    Marek K; Jennings D; Seibyl J
    Adv Neurol; 2003; 91():183-91. PubMed ID: 12442677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.